Description

Morphic Holding, Inc. is a biopharmaceutical company dedicated to the discovery and advancement of oral, small-molecule integrin-based therapies. These treatments are designed to address a broad spectrum of conditions, including autoimmune, cardiovascular, and metabolic diseases, as well as various forms of fibrosis and cancer. The company's principal therapeutic candidates include MORF-057, an a4ß7-specific integrin inhibitor targeting inflammation, currently undergoing Phase 1 clinical trials for inflammatory bowel disease and in preclinical development for idiopathic pulmonary fibrosis and other fibrotic ailments. Additionally, Morphic is progressing avß6 for fibrotic disorders and avß8 for solid tumor applications, alongside a pipeline of other innovative products. Morphic has established strategic collaborations, including a research partnership with Engitix Ltd concerning integrin technology for fibrostenotic IBD, an agreement with Schrödinger, LLC focused on integrin targets, and a licensing arrangement with Children's Medical Center Corporation for the global development and commercialization of products for human and veterinary therapeutic or diagnostic uses. Further collaborative efforts involve AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. for the discovery and development of integrin-based therapeutics. Established in 2014, Morphic Holding, Inc. operates from its headquarters in Waltham, Massachusetts.